Correction of high myopic astigmatism

Article

Results of surgical iLASIK procedure indicate better predictability

Wavefront guided ablations with Advanced CustomVue (Abbott Medical Optics, Santa Ana, California, USA) have been proven to be a very effective and safe way to correct myopia and myopic astigmatism.3 Among other technological features, the aforementioned procedure incorporates Iris Registration (IR), which is responsible for compensating any degree of ciclotorsion and pupil centroid shift that happens when the patient lies down under the laser and pupil changes size respectively. No study has been published yet addressing the outcome of this technology in patients with a high degree of astigmatism undergoing femtoLASIK surgery.

We designed a prospective open label comparative study with the objective of evaluating the efficacy, safety and predictability of the iLASIK procedure that combines the Advanced CustomVue procedure and Intralase FS60 (Abbott Medical Optics), in high myopic astigmatism and compare it with the standard femtoLASIK with the VISX S4 (Abbott Medical Optics). The main inclusion criteria was to have a compound myopic astigmatism with a cylinder ranging from 2 up to 5 D and sphere up to –6 D.4

Patients were followed up for a period of 3 months after surgery, including the following measurements uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), predictability, efficacy and safety. Refractive error and visual acuity were treated as continuous variables and analysed for significance by independent t test.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.